GlassScriptPhysician profile
Nicholas Igbinigie
NPI 1245915339
$4,721.27
in general payments reported to CMS, 2019-2025
13 companies · $4,222 in 2025
The $4,222 reported for 2025 was more than what 95% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $198 · 2024: $301 · 2025: $4,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,104 · Travel and Lodging: $617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,104.37 |
| Travel and Lodging | $616.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $3,181.85 | 2023-2025 | Ortholoc 2 Lapifuse, Augment Injectable, Hoffmann |
| Trimed, INC. | $945.50 | 2025 | |
| Axogen | $126.25 | 2025 | |
| Organogenesis INC. | $118.41 | 2024 | Nushield |
| Fusion Orthopedics USA, LLC | $64.34 | 2025 | |
| Treace Medical Concepts, INC. | $59.43 | 2024-2025 | |
| Trilliant Surgical LLC. | $44.84 | 2025 | Minimally Invasive Bunion Plate, Left |
| Medinc of Texas | $43.01 | 2025 | |
| Globus Medical, INC. | $37.89 | 2025 | Anthem |
| Paratek Pharmaceuticals, INC. | $33.23 | 2025 | Nuzyra |
| Solventum Corporation | $27.73 | 2024 | Promogran Prisma, Activ.A.C. |
| Checkpoint Surgical, INC | $20.77 | 2025 | Checkpoint Stimulators |
| Smith+Nephew, INC. | $18.02 | 2024 | Regranex, Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Igbinigie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.